Advertisement


Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?

2019 Quality Care Symposium

Advertisement

Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.



Related Videos

Issues in Oncology

Manali I. Patel, MD, on Community Practices: Enhancing Delivery of Value-Based Cancer Care

Manali I. Patel, MD, of Stanford Cancer Center, discusses enhancing value for patients with cancer treated by community practitioners at the end of life by also utilizing trained lay health workers in a novel intervention that reduced the use of acute care and emergency department visits while improving quality of life.

Issues in Oncology

Elena Martinez, PhD, MPH, on Diversity in Precision Oncology

Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.

Issues in Oncology
Global Cancer Care

Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review

Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).

Cost of Care
Issues in Oncology

Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials

Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase I trials (Abstract 8).

Issues in Oncology

Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists

Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in sharing knowledge from tumor board discussions at NCI-designated comprehensive cancer centers, with community oncologists on themednet.org. Currently, thoracic, breast, and GI cancers are included, with plans to expand the scope (Abstract 272).

Advertisement

Advertisement




Advertisement